DOCS
Neutral signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Doximity, Inc.
- Nom
- Doximity, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Information Services
- Bourse
- NYSE
- Capitalisation
- $6.0B
- Employés
- 880
- PDG
- Jeffrey A. Tangney
- Site web
- https://www.doximity.com
- Marché
- COOEHCEXASGHHQYICLR
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 7 290 titres (~194 835,90 $ US)
- Insiders
- Wampler Kira SchererYang Watkin Phoebe L.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$666,515
Avg sell (VWAP, 90d window) $31.37 vs last close $33.68 (+7.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$666,515 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Liquid $109,687,950/day · 20d vol
- Last synced
-
2026-10-22 21:10:26
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-14 | Sitaram Siddharth | Sell · S · 10b5-1 | 2,613 | $30.68 | $80,167 | Form 4 |
| 2026-10-01 | Wampler Kira Scherer | Sell · S · 10b5-1 | 2,000 | $28.91 | $57,820 | Form 4 |
| 2026-09-30 | Yang Watkin Phoebe L. | Sell · S · 10b5-1 | 1,290 | $26.71 | $34,456 | Form 4 |
| 2026-09-15 | Sitaram Siddharth | Sell · S · 10b5-1 | 2,077 | $26.02 | $54,044 | Form 4 |
| 2026-09-01 | Wampler Kira Scherer | Sell · S · 10b5-1 | 2,000 | $26.33 | $52,660 | Form 4 |
| 2026-08-25 | Wampler Kira Scherer | Sell · S · 10b5-1 | 2,000 | $24.95 | $49,900 | Form 4 |
| 2026-08-13 | Sitaram Siddharth | Sell · S · 10b5-1 | 1,770 | $24.94 | $44,144 | Form 4 |
| 2026-08-07 | Cabral Timothy S | Sell · S · 10b5-1 | 7,500 | $39.11 | $293,325 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-11-06 | Jonathan Jackson | Sale (Full) | $15,001 - $50,000 |
| 2025-08-25 | Jonathan Jackson | Purchase | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Despite DOCS's strong financial health (liquidity score 95, high margins, minimal debt), the catalyst score is critically low at 10, driven by multiple securities class action filings alleging fraud and revenue…
The first sentence of the analysis written for DOCS on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $586K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $586K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 6.09 · operating margin 33%
Suggested stop 24.86, nearest stored support minus 0.5 ATR(26.2% under the last close). Reward/risk to the next stored resistance is 0.72. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS New York, New York--(Newsfile Corp. - October 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between August 8, 2024 and May 13, 2026, both dates inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-10-19 Deadline Alert: Doximity, Inc. Investors Have Until November 16, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Class action covers investors who bought Doximity, Inc. securities between August 8, 2024 and May 13, 2026; complaint alleges the company failed to disclose material adverse facts Class action covers investors who bought Doximity, Inc. securities between August 8, 2024 and May 13, 2026; complaint alleges the company failed to disclose material adverse facts
- 2026-10-19 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between August 8, 2024 and May 13, 2026, both dates inclusive (the “Class Period”), of the important November 16, 2026 lead plaintiff deadline.
- 2026-10-19 DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 19, 2026LOS ANGELES, Oct. 19, 2026 /PRN
- 2026-10-19 DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Oct. 19, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of DOCS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
- 2026-10-19 Robbins LLP Urges DOCS Stockholders to Contact the Firm for Information About the Class Action Against Doximity, Inc. SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Doximity, Inc. (NYSE: DOCS) common stock between August 8, 2024 and May 13, 2026, inclusive (the "Class Period"). Doximity is a digital platform for medical professionals that combines health care news, workflow products, and clinician networking.
- 2026-10-19 Bronstein, Gewirtz & Grossman LLC Urges Doximity, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New class action for Doximity (DOCS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/16/2026
- 2026-10-19 DOCS Deadline Alert: Levi & Korsinsky Reminds Doximity, Inc. (DOCS) Investors of Securities Class Action Deadline on November 16, 2026 Notice to pension funds, asset managers, and fiduciaries: the pleading asserts that Doximity overstated how much its "Newsfeed" product drove revenue growth and misstated its competitive position, while DOCS holders absorbed three separate declines of 13%, 17%, and 23% Notice to pension funds, asset managers, and fiduciaries: the pleading asserts that Doximity overstated how much its "Newsfeed" product drove revenue growth and misstated its competitive position, while DOCS holders absorbed three separate declines of 13%, 17%, and 23%
- 2026-10-19 Doximity (NYSE:DOCS) CAO Sells $80,166.84 in Stock Doximity, Inc. (NYSE: DOCS - Get Free Report) CAO Siddharth Sitaram sold 2,613 shares of the firm''s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total value of $80,166.84. Following the completion of the transaction, the chief accounting officer owned 101,432 shares
- 2026-10-19 Kaplan Fox Notifies Investors of Doximity, Inc. (DOCS) of the Lead Plaintiff Deadline on November 16, 2026 New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) on behalf of investors that purchased or otherwise acquired Doximity common stock between August 8, 2024 and May 13, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Doximity and have suffered losses, you may CLICK HERE to contact us.
Market snapshot
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 89.1% | 90.2% | 89.3% | 87.2% | 88.4% | |
| Ebit Margin | 38.8% | 40.3% | 36.1% | 31.8% | 33.2% | |
| Ebitda Margin | 41.0% | 42.2% | 38.3% | 34.2% | 34.7% | |
| Operating Profit Margin | 33.3% | 39.9% | 34.5% | 29.9% | 33.0% | |
| Pretax Profit Margin | 38.8% | 46.2% | 39.0% | 31.8% | 33.2% | |
| Continuous Operations Profit Margin | 30.4% | 39.1% | 31.0% | 26.9% | 45.1% | |
| Net Profit Margin | 30.4% | 39.1% | 31.0% | 26.9% | 45.1% | |
| Bottom Line Profit Margin | 30.4% | 39.1% | 31.0% | 26.9% | 38.8% | |
| Current Ratio | 6.093 | 6.967 | 6.200 | 6.992 | 8.125 | |
| Quick Ratio | 6.093 | 6.967 | 6.200 | 6.992 | 8.125 | |
| Solvency Ratio | 1.217 | 1.287 | 0.887 | 0.721 | 1.417 | |
| Cash Ratio | 1.414 | 1.341 | 0.657 | 1.133 | 1.014 | |
| Price To Earnings Ratio | 22.190 | 48.765 | 33.859 | 55.828 | 64.309 | |
| Price To Earnings Growth Ratio | -1.886 | 0.928 | 0.982 | -1.966 | 0.112 | |
| Forward Price To Earnings Growth Ratio | -1.886 | 0.928 | 0.982 | -1.966 | 0.112 | |
| Price To Earnings Diluted Ratio | 23.776 | 52.279 | 36.681 | 61.094 | 74.414 | |
| Price To Earnings Diluted Growth Ratio | -2.030 | 0.965 | 1.023 | -2.516 | 0.154 | |
| Price To Book Ratio | 4.583 | 10.015 | 5.572 | 6.474 | 9.693 | |
| Price To Sales Ratio | 6.757 | 19.008 | 10.564 | 14.927 | 24.788 | |
| Price To Free Cash Flow Ratio | 13.724 | 40.648 | 28.169 | 36.069 | 70.450 | |
| Price To Operating Cash Flow Ratio | 13.348 | 39.677 | 27.282 | 34.827 | 67.279 | |
| Debt To Assets Ratio | 0.009 | 0.010 | 0.013 | 0.014 | 0.001 | |
| Debt To Equity Ratio | 0.011 | 0.011 | 0.016 | 0.016 | 0.001 | |
| Debt To Capital Ratio | 0.011 | 0.011 | 0.016 | 0.016 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.182 | 1.168 | 1.197 | 1.177 | 1.128 | |
| Working Capital Turnover Ratio | 0.749 | 0.672 | 0.594 | 0.515 | 0.763 | |
| Operating Cash Flow Ratio | 2.107 | 1.749 | 1.250 | 1.287 | 1.137 | |
| Operating Cash Flow Sales Ratio | 0.506 | 0.479 | 0.387 | 0.429 | 0.368 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.973 | 0.976 | 0.968 | 0.966 | 0.955 | |
| Debt Service Coverage Ratio | 99.732 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 154.719 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 32.053 | 22.045 | 12.656 | 11.486 | 116.230 | |
| Capital Expenditure Coverage Ratio | 36.423 | 41.880 | 31.735 | 29.043 | 22.218 | |
| Dividend Paid And Capex Coverage Ratio | 36.423 | 41.880 | 31.735 | 29.043 | 22.218 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 15.691 | 44.214 | 27.132 | 42.615 | 70.597 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 89.1% | ▼-1.1% | ▲0.2% |
| Ebit Margin | 38.8% | ▼-1.6% | ▲2.7% |
| Ebitda Margin | 41.0% | ▼-1.2% | ▲2.9% |
| Operating Profit Margin | 33.3% | ▼-6.6% | ▼-0.8% |
| Pretax Profit Margin | 38.8% | ▼-7.4% | ▲1.0% |
| Continuous Operations Profit Margin | 30.4% | ▼-8.7% | ▼-4.1% |
| Net Profit Margin | 30.4% | ▼-8.7% | ▼-4.1% |
| Bottom Line Profit Margin | 30.4% | ▼-8.7% | ▼-2.9% |
| Current Ratio | 6.093 | ▼-0.874 | ▼-0.782 |
| Quick Ratio | 6.093 | ▼-0.874 | ▼-0.782 |
| Solvency Ratio | 1.217 | ▼-0.070 | ▲0.112 |
| Cash Ratio | 1.414 | ▲0.073 | ▲0.302 |
| Price To Earnings Ratio | 22.191 | ▼-26.574 | ▼-22.800 |
| Price To Earnings Growth Ratio | -1.886 | ▼-2.814 | ▼-1.520 |
| Forward Price To Earnings Growth Ratio | -1.886 | ▼-2.814 | ▼-1.520 |
| Price To Earnings Diluted Ratio | 23.776 | ▼-28.504 | ▼-25.873 |
| Price To Earnings Diluted Growth Ratio | -2.030 | ▼-2.995 | ▼-1.549 |
| Price To Book Ratio | 4.583 | ▼-5.432 | ▼-2.685 |
| Price To Sales Ratio | 6.757 | ▼-12.251 | ▼-8.452 |
| Price To Free Cash Flow Ratio | 13.724 | ▼-26.923 | ▼-24.088 |
| Price To Operating Cash Flow Ratio | 13.348 | ▼-26.330 | ▼-23.135 |
| Debt To Assets Ratio | 0.009 | ▼-0.001 | ▼-0.000 |
| Debt To Equity Ratio | 0.011 | ▼-0.001 | ▼-0.000 |
| Debt To Capital Ratio | 0.011 | ▼-0.001 | ▼-0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.182 | ▲0.014 | ▲0.011 |
| Working Capital Turnover Ratio | 0.749 | ▲0.077 | ▲0.091 |
| Operating Cash Flow Ratio | 2.107 | ▲0.358 | ▲0.601 |
| Operating Cash Flow Sales Ratio | 0.506 | ▲0.027 | ▲0.072 |
| Free Cash Flow Operating Cash Flow Ratio | 0.973 | ▼-0.004 | ▲0.005 |
| Debt Service Coverage Ratio | 99.732 | ▲99.732 | ▲79.785 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 154.719 | ▲154.719 | ▲123.775 |
| Operating Cash Flow Coverage Ratio | 32.053 | ▲10.008 | ▼-6.841 |
| Capital Expenditure Coverage Ratio | 36.423 | ▼-5.457 | ▲4.163 |
| Dividend Paid And Capex Coverage Ratio | 36.423 | ▼-5.457 | ▲4.163 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 15.691 | ▼-28.524 | ▼-24.359 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $4.36B | $10.84B | $5.02B | $6.26B | $8.52B | |
| Enterprise value | $4.15B | $10.65B | $4.94B | $6.11B | $8.40B | |
| EV / Sales | 6.43x | 18.66x | 10.39x | 14.59x | 24.46x | |
| EV / Op. cash flow | 12.71x | 38.95x | 26.84x | 34.03x | 66.40x | |
| EV / Free cash flow | 13.07x | 39.91x | 27.71x | 35.25x | 69.53x | |
| EV / EBITDA | 15.69x | 44.21x | 27.13x | 42.62x | 70.60x | |
| Net debt / EBITDA | -0.79x | -0.82x | -0.45x | -0.99x | -0.94x | |
| Current ratio | 6.09x | 6.97x | 6.20x | 6.99x | 8.12x | |
| Income quality | 1.67x | 1.22x | 1.25x | 1.59x | 0.82x | |
| Graham number | $11 | $12 | $9 | $8 | $11 | |
| Graham net-net | $4 | $4 | $3 | $4 | $5 | |
| Tax burden | 78.4% | 84.7% | 79.7% | 84.7% | 135.8% | |
| Interest burden | 100.0% | 114.5% | 107.8% | 100.0% | 100.0% | |
| Working capital | $789.3M | $932.4M | $765.7M | $835.9M | $792.9M | |
| Invested capital | $934.8M | $1.05B | $885.6M | $960.8M | $829.3M | |
| Return on assets | 17.4% | 17.7% | 13.7% | 9.9% | 15.6% | |
| Operating ROA | 18.0% | 19.4% | 14.8% | 11.8% | 18.3% | |
| Return on tangible assets | 19.5% | 19.0% | 15.0% | 10.9% | 16.0% | |
| Return on equity | 20.6% | 20.6% | 16.4% | 11.7% | 17.6% | |
| Return on invested capital | 17.4% | 17.4% | 14.0% | 10.6% | 12.9% | |
| Return on capital employed | 22.2% | 20.6% | 17.6% | 12.5% | 12.9% | |
| Earnings yield | 4.5% | 2.1% | 2.9% | 1.8% | 1.8% | |
| Free cash flow yield | 7.3% | 2.5% | 3.5% | 2.8% | 1.4% | |
| Capex / Op. cash flow | 2.7% | 2.4% | 3.2% | 3.4% | 4.5% | |
| Capex / Depreciation | 62.3% | 61.2% | 56.5% | 60.1% | 113.0% | |
| Capex / Sales | 1.4% | 1.1% | 1.2% | 1.5% | 1.7% | |
| SG&A / Sales | 35.5% | 33.6% | 36.0% | 38.2% | 37.2% | |
| R&D / Sales | 20.3% | 16.3% | 17.2% | 19.1% | 18.1% | |
| Stock comp / Sales | 18.9% | 12.7% | 10.7% | 11.4% | 9.2% | |
| Intangibles / Total assets | 10.7% | 7.2% | 8.8% | 8.8% | 2.7% | |
| Days sales outstanding | 82d | 82d | 78d | 93d | 86d | |
| Days payables outstanding | 21d | 9d | 16d | 9d | 4d | |
| Operating cycle | 82d | 82d | 78d | 93d | 86d | |
| Cash conversion cycle | 61d | 73d | 62d | 85d | 82d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years